Continuing Education

ESMO-MORA

The Congress programme will be submitted for ESMO-MORA category 1 points accreditation.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possesses the necessary skills and standards for the practice of medical oncology.

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives

After attending this Congress, participants should be able to:

Identify current controversies in the management of patients with gastric, gastro-esophageal junction, and esophageal cancers
Describe the use of molecular markers for screening and prognosis of gastric cancer
Describe the epidemiology and pathogenesis of hepatocellular carcinoma
Discuss management of patients with hepatocellular carcinoma
Discuss management of patients with bile duct cancer
Identify neoadjuvant and adjuvant treatment options for patients with locally advanced and borderline resectable pancreatic cancer
Discuss current and new treatment options for patients with metastatic cancer of the pancreas
Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
Describe the use of molecular markers for screening and prognosis of colorectal cancer
Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
Comment on new agents in the treatment of colorectal cancer and the latest clinical trial results
Identify treatment strategies for early and locally advanced and metastatic rectal cancer
Distinguish between appropriate surgical techniques for the treatment of gastrointestinal, hepatobiliary, and pancreatic cancers
Understand the role of molecular markers in digestive cancers
Describe the immune mechanisms associated with gastrointestinal cancers
Understand relevant pathways and the role of new targets in GI cancer
Understand the best imaging modalities for diagnosis, staging, and response prediction in GI cancer
Understand the diagnostic and therapeutic pitfalls in rare GI cancers, including neuroendocrine tumors, GIST, and anal cancer
Discuss the endpoints of clinical trials and clinical trial methodology
Discuss the pharmacoeconomic principles involved in gastrointestinal cancers